Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
DOBUTREX (dobutamine) is an injectable small-molecule inotropic agent approved in 1978 for acute heart failure and cardiogenic shock. It works as a beta-1 adrenergic agonist to increase cardiac contractility and improve blood flow. The drug is administered intravenously in acute care hospital settings.
As a legacy injectable approaching loss of exclusivity, DOBUTREX team sizes are likely stable or contracting with focus on operational efficiency and transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.
DOBUTREX roles are primarily operational and commercial-execution focused, with limited visibility in job postings. This product is best suited for early-career professionals seeking stable specialty pharma or hospital sales experience, or mid-career professionals transitioning into operational/supply-chain functions.
Worked on DOBUTREX at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.